Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England

Christopher P Fox; William Townsend; John G Gribben; Tobias Menne; Nagesh Kalakonda; Paula Williams; Farah Toron; Emma Tyas; Miranda Cooper; Joshua Rickards; John Radford

doi:10.1002/jha2.970

Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England

Christopher P Fox, William Townsend, John G Gribben, Tobias Menne, Nagesh Kalakonda, Paula Williams, Farah Toron, Emma Tyas, Miranda Cooper, Joshua Rickards, John Radford

Research output: Contribution to journal › Article › peer-review

Abstract

Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression-free survival (PFS) and event-free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.

Original language	English
Pages (from-to)	992-997
Number of pages	6
Journal	eJHaem
Volume	5
Issue number	5
DOIs	https://doi.org/10.1002/jha2.970
Publication status	Published - Oct 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/jha2.970

Cite this

@article{70bbec6442864205a3805b72dcc1af11,

title = "Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England",

abstract = "Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression-free survival (PFS) and event-free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.",

author = "Fox, {Christopher P} and William Townsend and Gribben, {John G} and Tobias Menne and Nagesh Kalakonda and Paula Williams and Farah Toron and Emma Tyas and Miranda Cooper and Joshua Rickards and John Radford",

note = "{\textcopyright} 2024 The Author(s). eJHaem published by British Society for Haematology and John Wiley & Sons Ltd.",

year = "2024",

month = oct,

doi = "10.1002/jha2.970",

language = "English",

volume = "5",

pages = "992--997",

journal = "eJHaem",

issn = "2688-6146",

publisher = "John Wiley & Sons Ltd",

number = "5",

}

TY - JOUR

T1 - Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England

AU - Fox, Christopher P

AU - Townsend, William

AU - Gribben, John G

AU - Menne, Tobias

AU - Kalakonda, Nagesh

AU - Williams, Paula

AU - Toron, Farah

AU - Tyas, Emma

AU - Cooper, Miranda

AU - Rickards, Joshua

AU - Radford, John

PY - 2024/10

Y1 - 2024/10

N2 - Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression-free survival (PFS) and event-free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.

AB - Autologous stem-cell transplantation (ASCT) is standard therapy for relapsed/refractory large B-cell lymphoma (R/R LBCL), but many patients are either ineligible or unable to receive it. This retrospective study characterized outcomes in R/R LBCL, delineated by eligibility for, and receipt of, ASCT. Median progression-free survival (PFS) and event-free survival (EFS) for patients undergoing ASCT were 35.2 and 31.6 months (overall survival [OS] not reached). Median PFS, EFS, and OS were 4.3, 4.3, and 6.9 months for ineligible patients, and 2.7, 2.6, and 9.4 months for those eligible for but unable to receive ASCT. This highlights an unmet need for alternative therapies in patients unable to receive ASCT.

U2 - 10.1002/jha2.970

DO - 10.1002/jha2.970

M3 - Article

C2 - 39415902

SN - 2688-6146

VL - 5

SP - 992

EP - 997

JO - eJHaem

JF - eJHaem

IS - 5

ER -

Real-world outcomes of patients with relapsed/refractory large B-cell lymphoma receiving second-line therapy in England

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this